Beroni Group Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Beroni Group's earnings have been declining at an average annual rate of -21%, while the Biotechs industry saw earnings growing at 14.7% annually. Revenues have been declining at an average rate of 8.2% per year.
Belangrijke informatie
-21.0%
Groei van de winst
-17.9%
Groei van de winst per aandeel
| Biotechs Groei van de industrie | 9.6% |
| Inkomstengroei | -8.2% |
| Rendement op eigen vermogen | -50.7% |
| Nettomarge | -233.5% |
| Laatste winstupdate | 30 Jun 2022 |
Recente prestatie-updates uit het verleden
Geen updates
Recent updates
Opbrengsten en kosten
Hoe Beroni Group geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 22 | 2 | -4 | 6 | 0 |
| 31 Mar 22 | 2 | -4 | 6 | 0 |
| 31 Dec 21 | 2 | -3 | 5 | 0 |
| 30 Jun 21 | 2 | -3 | 4 | 0 |
| 31 Mar 21 | 2 | -4 | 5 | 0 |
| 31 Dec 20 | 2 | -5 | 6 | 0 |
| 30 Jun 20 | 1 | -8 | 9 | 0 |
| 31 Mar 20 | 2 | -8 | 9 | 0 |
| 31 Dec 19 | 2 | -8 | 9 | 0 |
| 30 Sep 19 | 2 | -6 | 8 | 0 |
| 30 Jun 19 | 2 | -5 | 6 | 0 |
| 31 Mar 19 | 2 | -3 | 5 | 0 |
| 31 Dec 18 | 2 | -2 | 5 | 0 |
| 30 Sep 18 | 2 | -2 | 5 | 0 |
| 30 Jun 18 | 2 | -2 | 5 | 0 |
| 31 Mar 18 | 2 | -2 | 4 | 0 |
| 31 Dec 17 | 2 | -1 | 3 | 0 |
| 30 Sep 17 | 3 | 0 | 3 | 0 |
| 30 Jun 17 | 3 | 0 | 3 | 0 |
| 31 Mar 17 | 4 | 0 | 2 | 0 |
| 31 Dec 16 | 4 | 0 | 2 | 0 |
| 31 Dec 15 | 1 | 0 | 1 | 0 |
Kwaliteitswinsten: BTG is currently unprofitable.
Groeiende winstmarge: BTG is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: BTG is unprofitable, and losses have increased over the past 5 years at a rate of 21% per year.
Versnelling van de groei: Unable to compare BTG's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: BTG is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-9.8%).
Rendement op eigen vermogen
Hoge ROE: BTG has a negative Return on Equity (-50.72%), as it is currently unprofitable.